Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].

Der Internist - 1 Jul 2008

Seeringer A, Kirchheiner J

Abstract excerpt

The efficacy of a drug therapy is influenced by many different factors such as age, weight, comorbidity and co-medication, which vary between patients, as well as fixed parameters such as gender and pharmacogenetic characteristics. Many enzymes involved in drug metabolism are genetically polymorphic, which means that their activity differs depending on a certain genotype. Drugs will be metabolized slowly in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Drug Administration Schedule

Share to Genetic Predisposition to Disease

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 18551264
DOI: 10.1007/s00108-008-2125-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].PMID 18551264Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

Cytochrome P450 genotype-guided drug therapies: An update on current states.Semantic proximity Read ↗

[How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].Semantic proximity Read ↗

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages.Semantic proximity Read ↗

CYP2C19 polymorphism in relation to the pharmacotherapy optimization of commonly used drugsSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.Semantic proximity Read ↗

Genotype and phenotype relationship in drug metabolism.Semantic proximity Read ↗

[Importance of genetic polymorphism of cytochrome P450 isoenzymes for the choice and regimes of antidepressant and antipsychotic dosing on an individual basis].Semantic proximity Read ↗

From genes to drugs: CYP2C19 and pharmacogenetics in clinical practiceSemantic proximity Read ↗

Cytochrome P450 in Pharmacogenetics: An Update.Semantic proximity Read ↗

Evidence based drug dosing and pharmacotherapeutic recommendations per genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.